NasdaqGS:INDVPharmaceuticals
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Q1 Beat, Raised 2026 Guidance And Buyback News
Indivior Pharmaceuticals (INDV) is back on investors' radars after a busy stretch that combined strong Q1 2026 results, a raised full year revenue outlook, and a fresh accelerated share repurchase plan.
See our latest analysis for Indivior Pharmaceuticals.
The recent Q1 beat, raised 2026 guidance, and the new accelerated share repurchase agreement have all coincided with strong momentum, with a 27.93% 1 month share price return and a very large 1 year total shareholder return that far...